Phase I clinical and pharmacology study of 502U83 given as a 24-h continuous intravenous infusion
暂无分享,去创建一个
R. Schilsky | M. Ratain | N. Vogelzang | L. Janisch | N. Clendeninn | V. Lucas | J. Hohneker | J. Ravitch | R. Tuttle
暂无分享,去创建一个
R. Schilsky | M. Ratain | N. Vogelzang | L. Janisch | N. Clendeninn | V. Lucas | J. Hohneker | J. Ravitch | R. Tuttle